Synthesis and preliminary biological evaluation of a new pyridocarbazole derivative covalently linked to a thymidine nucleoside as a potential targeted antitumoral agent. I

Chemical and Pharmaceutical Bulletin

Volumn 51, Issue 8, 2003, Pages 971-974

  Saturnino, Carmela ^a   Buonerba, Mariafrancesca ^a   Boatto, Gianpiero ^b   Pascale, Maria ^a   Moltedo, Ornella ^a   De Napoli, Lorenzo ^c   Montesarchio, Daniela ^c   Lancelot, Jean Charles ^d   De Caprariis, Paolo ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

Author keywords

Anticancer; Cytotoxicity; Ellipticine

Indexed keywords

ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; DNA; ELLIPTICINE DERIVATIVE; PRODRUG; THYMIDINE; PYRIDONE DERIVATIVE; PYRIMIDINE NUCLEOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIVISION; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; HUMAN CELL; HYDROLYSIS; PLASMA; TUMOR CELL; DRUG DELIVERY SYSTEM; DRUG SCREENING; METHODOLOGY; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARBAZOLES; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; PYRIDONES; PYRIMIDINE NUCLEOSIDES; THYMIDINE;

EID: 2142771242     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.51.971     Document Type: Article

References (18)

1. Wang J. C., Annu. Rev. Biochem., 65, 635-692 (1996).
2. Monks N. R., Blankey D. C., East S. J., Dowell R. I., Caluete J. A., Curtin N. J., Arris C. E., Newell D. R., Eur. J. Cancer, 11, 1543-1552 (2002).
3. Lancelot J. C., Letois B., Rault S., Dung N., Saturnino C., Robba M., Gaz. Chim. Ital., 121, 301-307 (1991).
4. Moinet V., Tabka T., Poulain L., Godard T., Lecheurel M., Saturnino C., Lancelot J. C., Le Talaer J., Gauduchon P., Anti-Cancer Drug Design, 15, 109-118 (2000).
5. Moinet V., Tabka T., Sichel F., Gauduchon P., Le Talaer J., Saturnino C., Lancelot J. C., Robba M., Eur. J. Med. Chem., 32, 113-122 (1997).
6. Moinet V., Tabka T., Gauduchon P., Le Talare J. Y., Lancelot J. C., Letois B., Saturnino C., Rault S., Robba M., J. Toxicol. Clinique Exp., 1, 3-4 (1992).
7. Teran C., Santana L., Teejeira M., Uriarte E., De Clarcq E., Chem. Pharm. Bull., 48, 293-295 (2000).
8. Wueest T., Gerlach E., Banbrjee D., Gersjach D., Pfizenmaier K., Oncogene, 9, 844-849 (2002).
9. Kao C. K., Waki A., Sassaman M. B., Jagoda E., Srajek L. P., Ravasi L., Shimoji K., Eckelman W. C., Nucl. Med. Biol., 29, 527-535 (2002).
10. Hergueta A. R., Fernandez F., Lopez C., Balzanini J., de Clarcq E., Chem. Pharm. Bull., 49, 1174-1177 (2001).
11. Gumina G., Song G. Y., Chu C. K., FEMS Microb. Lett., 202, 9-15 (2001).
12. Sugikawa E., Hosoi T., Yazaki N., Gamanuma M., Nakanishi N., Ohashi M., Anticancer Res., 19, 3099-3108 (1999).
13. Mizutani H., Tada-Oikawa S., Hiraku Y., Oikawa S., Kojima M., Kawanishi S., J. Biol. Chem., 277, 30684-30689 (2002).
14. Owuor Ed., Kong An., Biochem. Pharmacol., 64, 765-770 (2002).
15. Maeda H., Sawa T., Konno T., J. Controll. Release, 74, 47-61 (2001).
16. Ferlin M. G., Chiarelotto G., Marzano C., Severin E., Baccichetti F., Carlassare F., Simionato M., Bordin F., Il Farmaco, 53, 431-437 (1998).
17. Monnot M., Mauffret O., Simon V. Lescot E., Psaume B., Sacier J. M., Charra M., Belehradek J., Jr., Fermandjian S., J. Biol. Chem., 266, 1820-1829 (1991).
18. Ryan J. J., Danish R., Gottlieb C. A., Clarke M. F., Mol. Cell. Biol., 13, 711-719 (1993).